ANGLE PLC has opened up "a major market opportunity" with breast cancer partnership

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Thomas Warner from Proactive after announcing a development partnership with BioView.

The partnership will see the two firms develop to create a circulating tumour cell (CTC) HER2 assay for breast cancer that could ultimately enable hospitals worldwide to access technology that measures HER2 status in breast cancer patients.

Newlands says it has opened up "a major market opportunity" with the partnership.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  257.37
+0.00 (0.00%)
AAPL  349.21
+0.00 (0.00%)
AMD  489.19
+0.00 (0.00%)
BAC  48.57
+0.00 (0.00%)
GOOG  271.02
+0.00 (0.00%)
META  596.22
+0.00 (0.00%)
MSFT  498.30
+0.00 (0.00%)
NVDA  145.98
+0.00 (0.00%)
ORCL  110.57
+0.00 (0.00%)
TSLA  374.41
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.